Target therapy in metastatic renal cell carcinoma / 国际肿瘤学杂志

ABSTRACT

The targeted agents of metastatic renal cell carcinoma include the inhibitor of the VHL- HIF-VEGF pathway(sunitinib、 sorafenib、 bevacizumab、 Axitinib) and the mTOR pathway (Temsirolimus, Everoli-mus). These targeted chugs suggest the onset of a new therapeutic era for patients with metastatic renal cell car-cinoma. It is necessary to pay more attention to the side effect. The therapeutic scheme choice of patients and the treatment effect of the non-clear cell carcinomal need further studies.